Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice

Oncology Reports

Volumn 9, Issue 1, 2002, Pages 199-203

  Giermasz, Adam ^a   Makowski, Marcin ^a   Nowis, Dominika ^a   Jalili, Ahmad ^a   Malgorzata, M A J ^a   Dabrowska, Anna ^a,b   Czajka, Anna ^a   Jakobisiak, Marek ^a   Golab, Jakub ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Actinomycin D; Butyrate; Melanoma; Mouse; TNF

Indexed keywords

DACTINOMYCIN; DIAGNOSTIC AGENT; FORMAZAN; MTT FORMAZAN; TETRAZOLIUM; TRIACYLGLYCEROL; TRIBUTYRIN; TUMOR NECROSIS FACTOR;

ANIMAL; ARTICLE; CELL SURVIVAL; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL MELANOMA; MALE; METABOLISM; MOUSE; MOUSE STRAIN;

ANIMAL; CELL SURVIVAL; DACTINOMYCIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FORMAZANS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; SUPPORT, NON-U.S. GOV'T; TETRAZOLIUM SALTS; TRIGLYCERIDES; TUMOR NECROSIS FACTOR;

EID: 0036134016     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.1.199     Document Type: Article

References (27)

1. Cummings JH: Short chain fatty acids in the human colon. Gut 22: 763-779, 1981.
2. Heerdt BG, Houston MA, Anthony GM and Augenlicht LH: Initiation of growth arrest and apoptosis of MCF-7 mammary carcinoma cells by tributyrin, a triglyceride analogue of the short-chain fatty acid butyrate, is associated with mitochondrial activity. Cancer Res 59: 1584-1591, 1999. (Pubitemid 29160130)
3. Lallemand F, Courilleau D, Buquet-Fagot C, Atfi A, Montagne MN and Mester J: Sodium butyrate induces G2 arrest in the human breast cancer cells MDA-MB-231 and renders them competent for DNA rereplication. Exp Cell Res 247: 432-440, 1999. (Pubitemid 29394781)
4. Vaziri C, Stice L and Faller DV: Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ 9: 465-474, 1998. (Pubitemid 28345871)
5. Abe M and Kufe DW: Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells. Cancer Res 44: 4574-4577, 1984. (Pubitemid 14008780)
6. Augeron C and Laboisse CL: Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res 44: 3961-3969, 1984. (Pubitemid 14041623)
7. Golab J, Zagozdzon R, Kaminski R, Kozar K, Gryska K, Izycki D, Mackiewicz A, Stoklosa T, Giermasz A, Lasek W and Jakóbisiak M: Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia 15: 613-620, 2001. (Pubitemid 32266729)
8. Zimra Y, Wasserman L, Maron L, Shaklai M, Nudelman A and Rephaeli A: Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. J Cancer Res Clin Oncol 123: 152-160, 1997. (Pubitemid 27153353)
9. Conley BA, Egorin MJ, Tait N, Rosen DM, Sausville EA, Dover G, Fram RJ and van Echo DA: Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res 4: 629-634, 1998. (Pubitemid 28193561)
10. Douillard JY, Bennouna J, Vavasseur F, Deporte-Fety R, Thomare P, Giacalone F and Meflah K: Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer. Cancer Immunol Immunother 49: 56-61, 2000. (Pubitemid 30430679)
11. Davis T, Kennedy C, Chiew YE, Clarke CL and deFazio A: Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression innormal mammary epithelial cells. Clin Cancer Res. 6: 4334-4342, 2000.
12. Pellizzaro C, Coradini D, Daniotti A, Abolafio G and Daidone MG: Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines. Int J Cancer 91: 654-657, 2001. (Pubitemid 32115260)
13. Rabizadeh E, Shaklai M, Nudelman A, Eisenbach L and Rephaeli A: Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by abutyric acid prodrug. FEBS Lett 328: 225-229, 1993. (Pubitemid 23238092)
14. Xu D, Gruber A, Peterson C and Pisa P: Supression of telomerase activity in HL60 cells after treatment with differentiating agents. Leukemia 10: 1354-1357, 1996. (Pubitemid 26261433)
15. Le Gros GS, Herbert AG and Watson ID: The effects of sodium butyrate on lymphokine production. Lymphokine Res 4: 221-227, 1987.
16. Saemann MD, Bohmig GA, Osterreicher CH, Burtscher H, Parolini O, Diakos C, Stockl J, Horl WH and Zlabinger GJ: Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J 14: 2380-2382, 2000.
17. Wang LS, Chow KC and Wu CW: Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium-butyrate. Br J Cancer 80: 1617-1622, 1999.
18. Alexander RB, Isaacs JT and Coffey DS: Tumor necrosis factor enhances the in vitro and in vivo efficacy of chemotherapeutic drugstargeted at DNA topoisomerase II in the treatment of murine bladder cancer. J Urol 138: 427-429, 1987. (Pubitemid 17132879)
19. Lasek W, Giermasz A, Kuc K, Wankowicz A, Feleszko W, Golab J, Zagozdzon R, Stoklosa T and Jakobisiak M: Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results. Int J Cancer 66: 374-379, 1996.
20. Golab J, Stoklosa T, Zagozdzon R, Kaca A, Giermasz A, Pojda Z, Machaj E, Dabrowska A, Feleszko W, Lasek W, Iwan-Osiecka A and Jakóbisiak M: G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice. Ann Oncol 9: 63-69, 1998. (Pubitemid 28125766)
21. Giermasz A, Nowis D, Jalili A, Basak G, Marczak M, Makowski M, Czajka A, Mlynarczuk I, Hoser G, Stoklosa T, Lewandowski S and Jakóbisiak M: Antitumor activity of tributyrin in murine melanoma model. Cancer Lett 164: 143-148, 2001.
22. Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D and Paraskeva C: Sodium butyrate induces apoptosis in human colonic tumor cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer 55: 498-505, 1993. (Pubitemid 23300605)
23. Segain JP, Raingeard de la Bletiere D, Bourreille A. Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C. Blottiere HM and Galmiche JP: Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 47: 397-403, 2000.
24. Creasey AA, Doyle LV, Reynolds MT, Jung T, Lin LS and Vitt CR: Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor andnormal cell lines. Cancer Res 47: 145-149, 1987. (Pubitemid 17002114)
25. Darzynkiewicz Z, Carter SP and Old LJ: Effect of recombinant tumor necrosis factor on HL-60 cells: cell-cycle specificity and synergism with actinomycin D. J Cell Physiol 130: 328-335, 1987. (Pubitemid 17051284)
26. Giardina C, Boulares H and Inan MS: NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species. Biochim Biophys Acta 1448: 425-438, 1999. (Pubitemid 29070867)
27. Kovarikova M, Pachernik J, Hofmanova J, Zadak Z and Kozubik A: TNF-alpha modulates the differentiation induced by butyrate in the HT-29 human colonadenocarcinoma cell line. Eur J Cancer 36: 1844-1852, 2000. (Pubitemid 30639505)